Reactive oxygen species in melanoma and its therapeutic implications

Melanoma Research

Volumn 17, Issue 6, 2007, Pages 400-409

  Wittgen, Hanneke G M ^a   Van Kempen, Léon C L T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Melanoma development; Metastasis; Reactive oxygen species

Indexed keywords

2 METHOXYESTRADIOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CAROTENOID; CUPRIC ION; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; FLAVONOID; MELANIN; POLYPHENOL; REACTIVE OXYGEN METABOLITE; RESVERATROL; VITAMIN D;

ANTIOXIDANT ACTIVITY; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL METABOLISM; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MECHANISM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; MELANOCYTE; MELANOGENESIS; MELANOMA; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET RADIATION;

ANIMALS; ANTIOXIDANTS; ELECTRON TRANSPORT; HUMANS; MELANINS; MELANOMA; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 36048989628     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f1d312     Document Type: Review

References (94)

1. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol 2005; 37:2478-2503.
2. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007; 115:81-103.
3. Rashba-Step J, Turro NJ, Cederbaum AI. Increased N. Arch Biochem Biophys 1993; 300:401-408.
4. Del Rio LA, Sandalio LM, Palma JM, Bueno P, Corpas FJ. Metabolism of oxygen radicals in peroxisomes and cellular implications. Free Radic Biol Med 1992; 13:557-580.
5. Forman HJ, Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002; 166:S4-S8.
6. Babior BM. The NADPH oxidase of endothelial cells. IUBMB Life 2000; 50:267-269.
7. Ichihashi M, Ueda M, Budiyanto A, Bito T, Oka M, Fukunaga M, et al. UV-induced skin damage. Toxicology 2003; 189:21-39.
8. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 1997; 272:217-221.
9. Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006; 41:1521-1533.
10. Bienert GP, Moller ALB, Kristiansen KA, Schulz A, Moller IM, Schjoerring JK, et al. Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes. J Biol Chem 2007; 282:1183-1192.
11. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001; 52:3-6.
12. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005; 97:967-974.
13. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007; 13:789-794.
14. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408:239-247.
15. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002; 33:337-349.
16. Cheng GC, Schulze PC, Lee RT, Sylvan J, Zetter BR, Huang H. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004; 300:297-307.
17. DeYulia GJ Jr, Carcamo JM, Borquez-Ojeda O, Shelton CC, Golde DW. Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling. Proc Natl Acad Sci U S A 2005; 102:5044-5049.
18. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, et al. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 2006; 25:3689-3698.
19. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000; 32:157-170.
20. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192:1-15.
21. Rudolph J. Redox regulation of the Cdc25 phosphatases. Antioxid Redox Signal 2005; 7:761-767.
22. 2-induced apoptosis via MAP kinase-MKP-1 pathway. Free Radic Biol Med 2004; 36:985-993.
23. Minetti M, Mallozzi C, Di Stasi AM. Peroxynitrite activates kinases of the src family and upregulates tyrosine phosphorylation signaling. Free Radic Biol Med 2002; 33:744-754.
24. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 2006; 8:1775-1789.
25. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006; 126:2565-2575.
26. Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, et al. Molecular events in melanoma development and progression. Front Biosci 1998; 3:D1005-D1010.
27. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147.
28. Van Kempen LC, van Muijen GN, Ruiter DJ. Stromal responses in human primary melanoma of the skin. Front Biosci 2005; 10:2922-2931.
29. Elder DE. Pathology of melanoma. Clin Cancer Res 2006; 12:2308s-2311s.
30. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005; 8:443-454.
31. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
32. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64:7002-7010.
33. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729.
34. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63:756-759.
35. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003; 104:527-532.
36. Verhaegen M, Bauer JA, Martin dl V, Wang G, Wolter KG, Brenner JC, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66:11348-11359.
37. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72:1493-1505.
38. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-436.
39. Ueda Y, Richmond A. NF-kappaB activation in melanoma. Pigment Cell Res 2006; 19:112-124.
40. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118:915-922.
41. Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 1992; 11:3323-3335.
42. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1991; 354:494-496.
43. Westermarck J, Lohi J, Keski-Oja J, Kahari VM. Okadaic acid-elicited transcriptional activation of collagenase gene expression in HT-1080 fibrosarcoma cells is mediated by JunB. Cell Growth Differ 1994; 5:1205-1213.
44. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunBFra1 and JunB-FosB heterodimers. Biochem J 2003; 369:485-496.
45. Kim MH, Cho HS, Jung M, Hong MH, Lee SK, Shin BA, et al. Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells. Int J Oncol 2005; 26:1669-1674.
46. De Wit NJ, van Muijen GN, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004; 44:517-541.
47. Vartanian A, Baryshnikov AY. Crosstalk between apoptosis and antioxidants in melanoma vasculogenic mimicry. Adv Exp Med Biol 2007; 601:145-153.
48. Clarijs R, Ruiter DJ, De Waal RM. Pathophysiological implications of stroma pattern formation in uveal melanoma. J Cell Physiol 2003; 194:267-271.
49. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3:411-421.
50. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Research 2006; 66:7833-7836.
51. Skoyum R, Eide K, Berg K, Rofstad EK. Energy metabolism in human melanoma cells under hypoxic and acidic conditions in vitro. Br J Cancer 1997; 76:421-428.
52. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, et al. Reactive oxygen species from NAD(P)H: quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells. Am J Physiol Cell Physiol 2001; 280:C659-C676.
53. Stryer L. Biochemistry. New York: W.H. Freedman and company; 1988.
54. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
55. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998; 63:854-865.
56. van Kempen LC, Ruiter D, van Muijen GN, Coussens LM. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 2003; 82:539-548.
57. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37.
58. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006; 42:728-734.
59. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115:813-824.
60. MacKie RM. Long-term health risk to the skin of ultraviolet radiation. Prog Biophys Mol Biol 2006; 92:92-96.
61. Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44:837-846.
62. Meyskens FL Jr, Farmer PJ, nton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004; 10:2581-2583.
63. Pavel S, van NF, van der MH, Out C, Pizinger K, Cetkovska P, et al. Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi. Eur J Cancer 2004; 40:1423-1430.
64. McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol 1998; 35:5-12.
65. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004; 64:13-18.
66. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005; 65:2387-2396.
67. Sander CS, Chang H, Hamm F, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004; 43:326-335.
68. Lincoln DT, li Emadi EM, Tonissen KF, Clarke FM. The thioredoxin- thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003; 23:2425-2433.
69. Baldi A, Lombardi D, Russo P, Palescandolo E, De LA, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 2005; 11:3175-3183.
70. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-812.
71. Stryker WS, Stampfer MJ, Stein EA, Kaplan L, Louis TA, Sober A, et al. Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol 1990; 131:597-611.
72. Bain C, Green A, Siskind V, Alexander J, Harvey P. Diet and melanoma. An exploratory case-control study. Ann Epidemiol 1993; 3:235-238.
73. Kirkpatrick CS, White E, Lee JA. Case-control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am J Epidemiol 1994; 139:869-880.
74. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042-1051.
75. Feskanich D, Willett WC, Hunter DJ, Colditz GA. Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. Br J Cancer 2003; 88:1381-1387.
76. Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 2007; 137:2098-2105.
77. Le Marchand L, Saltzman BS, Hankin JH, Wilkens LR, Franke AA, Morris SJ, et al. Sun exposure, diet, and melanoma in Hawaii Caucasians. Am J Epidemiol 2006; 164:232-245.
78. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88:1560-1570.
79. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
80. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-220.
81. Fuggetta MP, D'Atri S, Lanzilli G, Tricarico M, Cannavo E, Zambruno G, et al. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma Res 2004; 14:189-196.
82. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, Rankin GO. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 2006; 136:2542-2546.
83. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16:1246-1252.
84. Lao CD, Demierre MF, Sondak VK. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 2006; 6:1559-1568.
85. Yusuf N, Irby C, Katiyar SK, Elmets CA. Photoprotective effects of green tea polyphenols. Photodermatol Photoimmunol Photomed 2007; 23:48-56.
86. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 2002; 1:197-204.
87. Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47:6914-6920.
88. Dobos J, Timar J, Bocsi J, Burian Z, Nagy K, Barna G, et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 2004; 112:771-776.
89. Heikkila RE, Cohen G. The inactivation of copper-zinc superoxide dismutase by diethyldithiocarbamate. In: Michelson AM, McCord JM, Fridovich I, editors. Superoxide and superoxide dismutases. London: Academic Press; 1977:367-373.
90. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407:390-395.
91. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-239.
92. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release 2005; 109:101-107.
93. Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M. Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clin Exp Metastasis 2006; 23:269-278.
94. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med 2006; 41:1449-1458.